RxDoctor Payments Data

Tsovinar Tekkelian, MD

Clinical Cardiac Electrophysiology · Glendale, CANPI 1558447607

Payments from drug & device makers

$14,427in general payments, 2019–2025

Across 679 payments — averaging $21.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$1K
  • Novo Nordisk$1K
  • Astellas Pharma US Inc$826
  • Ironwood Pharmaceuticals, Inc$572
  • Takeda Pharmaceuticals U.S.A., Inc.$528
  • plus $8K from 51 others

What the payments were for

  • Food & beverage$14,01297%
  • Education$3993%
  • Gifts$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)119$2,293
Amgen(2 entities)55$1,424
Novo Nordisk75$1,127
Astellas Pharma US Inc38$826
Ironwood Pharmaceuticals, Inc26$572
Takeda Pharmaceuticals U.S.A., Inc.33$528
AstraZeneca23$520
Boehringer Ingelheim25$509
Amarin Pharma, Inc.24$493
Lundbeck LLC19$485
GSK18$451
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC20$392
Ardelyx, Inc.14$389
Lilly USA, LLC17$385
Sanofi-aventis U.S. LLC18$371
Novartis14$319
Pfizer17$304
Kowa Pharmaceuticals America, Inc.9$279
Nestle Healthcare Nutrition Inc.14$234
Abbott2$223
Almatica Pharma LLC8$197
Vivus LLC7$150
Bayer6$147
Sumitomo Pharma America, Inc.6$145
Idorsia Pharmaceuticals US Inc2$143
Merck8$137
Aimmune Therapeutics, Inc.5$137
Esperion Therapeutics, Inc.6$126
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$122
Otsuka America Pharmaceutical, Inc.4$92
Bausch Health US, LLC3$82
Phathom Pharmaceuticals, Inc.4$81
Corium, LLC3$79
Scilex Pharmaceuticals Inc.4$63
Biohaven Pharmaceutical Holding Company Ltd.2$52
Shield Therapeutics Inc2$48
Sanofi1$41
Redhill Biopharma Inc.2$37
OPKO Pharmaceuticals, LLC2$35
Hikma Pharmaceuticals USA2$35
Regeneron Healthcare Solutions, Inc.1$29
Adamas Pharmaceuticals, Inc.2$28
Promius Pharma LLC1$26
Vertiflex, Inc.1$24
Arbor Pharmaceuticals, Inc.1$24
LEO Pharma Inc.1$23
E.r. Squibb & Sons, L.L.C.1$23
Eyevance Pharmaceuticals LLC1$22
Biohaven Pharmaceuticals, Inc.1$22
Biogen1$21
Teva Pharmaceuticals USA, Inc.1$17
Eisai Inc.1$17
Athena Bioscience, LLC1$17
Ascend Therapeutics US, LLC1$16
Sebela Pharmaceuticals Inc.1$16
Concordia Pharmaceuticals Inc.1$16
Dexcom, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,427 in reported general payments places this provider in the 25th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$449,595
Medicare patients
778
Services billed
7,103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate883$1,201,362
CreonLipase/Protease/Amylase522$727,195
OzempicSemaglutide546$551,164
LinzessLinaclotide861$509,308
Diclofenac Sodium1,138$471,346
JanumetSitagliptin Phos/Metformin Hcl743$465,381
Diclofenac Potassium285$417,884
VascepaIcosapent Ethyl1,547$409,899
MyrbetriqMirabegron594$276,788
MounjaroTirzepatide236$264,263
Zileuton ErZileuton109$247,326
JardianceEmpagliflozin319$216,717
ZenpepLipase/Protease/Amylase163$208,385
EliquisApixaban332$200,367
Fenofibrate250$185,875

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Restasis$2,293$1,291,6441,459 claims
MerckJanumet, Januvia$137$632,8171,012 claims
Novo NordiskOzempic$1,127$551,164546 claims
Boehringer IngelheimJardiance, Tradjenta, Jentadueto$509$420,665705 claims
Lilly USA, LLCMounjaro, Trulicity$385$342,196318 claims
Astellas Pharma US IncMyrbetriq$826$276,788594 claims
Aimmune Therapeutics, Inc.Zenpep$137$208,385163 claims
PfizerEliquis$304$200,367332 claims
AmgenProlia$1,424$126,54873 claims
GSKTrelegy Ellipta$451$75,032118 claims
AstraZenecaFarxiga$520$67,33399 claims
NovartisEntresto$319$49,35778 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →